Sermorelin 5mg

▎Sermorelin Structure

▎Sermorelin Research

Molecular Background

Sermorelin (GHRH 1–29-NH₂) is a synthetic 29-amino-acid peptide corresponding to the N-terminal 1–29 sequence of human growth hormone-releasing hormone, with an amidated C-terminus. PubChem lists Sermorelin under CID 16132413, with the molecular formula C149H246N44O42S and a molecular weight of approximately 3357.9 g/mol.[7]

Research Progress

Halmos et al. reviewed the signaling mechanisms of the growth hormone-releasing hormone receptor (GHRH-R), including the pituitary receptor and receptor splice variants reported in extrapituitary tissues. The authors described GHRH-R as a G protein-coupled receptor whose activation is associated primarily with adenylate cyclase–cAMP signaling, while additional signaling pathways have been reported in different cellular contexts. Because this work addresses GHRH and GHRH analog signaling broadly, the findings provide receptor-level context for Sermorelin rather than a direct experimental evaluation of a specific Sermorelin research material.[2,3]

Fig1. Schematic overview of GH–IGF-1-axis compounds and receptor pathways presented in the cited review.[1]

The source figure summarizes receptor targets and signaling pathways discussed for GHRH analogs, growth hormone-releasing peptides, GH-related compounds, and IGF-1-related compounds. Arrows and pathway labels reflect the authors’ schematic presentation and should be interpreted within the context of the cited review.[1]

González-López et al. synthesized several short peptides, including Sermorelin-derived fragments (1–11), (13–20), and (22–29), and examined their behavior after exposure to human blood, trypsin, and chymotrypsin. Products were analyzed by HPLC-DAD to compare protein-binding and enzymatic-stability profiles. The authors reported that GHRP-4, GHRP-6, and the Sermorelin (22–29) fragment remained stable under the tested blood and enzyme conditions and could be considered as in-house internal standards for analytical work. These experiments evaluated Sermorelin fragments rather than intact 29-amino-acid Sermorelin.[4]

Fig2. Chromatographic profiles of Sermorelin-derived peptide fragments in the cited stability study.[4]

(a) Sermorelin (1–11); (b) Sermorelin (13–20); and (c) Sermorelin (22–29) after exposure to trypsin (left) and chymotrypsin (right) at the time points reported in the original publication.[4]

Otin et al. developed a capillary electrophoresis method using dimethyl-β-cyclodextrin as a chiral selector for the separation of GHRH analogs, including Sermorelin and CJC-1293. The investigators also evaluated electrokinetic preconcentration approaches and reported that polarity-switching large-volume sample stacking produced greater signal enhancement than the sweeping method under the tested conditions. Following optimization, the method separated the GHRH analogs with limits of detection between 75 and 200 ng/mL and was applied to desalted urine samples.[5]

Fig3. Effect of cyclodextrin concentration on the resolution between Sermorelin and CJC-1293 in the cited capillary-electrophoresis study. Conditions included a 60 cm × 50 μm i.d. fused-silica capillary (effective length 50 cm), 100 mM lithium phosphate at pH 3.5, 200 nm detection, 30 kV, and 25°C. Complete sample and separation conditions are reported in the original publication.[5]

Fig4. Simplified schematic workflow for smart samplers (top) and dried serum spots (bottom)^[6].
The major difference is that in the smart sampler workflow (top) the selective binding of the target analytes to the antibodies immobilized to the sampling paper allows for a washing step prior to the elution of the paper.

Research Limitations

The studies summarized above address receptor signaling and analytical characterization rather than the clinical performance of a laboratory research material. In particular, the enzymatic-stability study by González-López et al. evaluated short Sermorelin-derived fragments rather than intact Sermorelin, so its findings should not be used to assign a serum half-life, systemic bioavailability, or degradation rate to the complete 29-amino-acid peptide.[4]

Analytical results also depend on the exact chemical form being measured. PubChem distinguishes Sermorelin from Sermorelin acetate, and analytical studies may use different matrices, sample-preparation procedures, or reference materials.[4-7] Comparisons across publications should therefore remain tied to the specific molecular form and analytical conditions described by each source.

COCER Peptides presents Sermorelin solely for laboratory research and analytical use. It is not intended for human or veterinary use. The research described above summarizes findings reported in third-party publications and is not a statement of clinical efficacy, safety, diagnosis, treatment, prevention, or an instruction for use.

▎Relevant Citations

References

[1] Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration[J]. Frontiers in Endocrinology, 2026,17:1822475.

DOI:10.3389/fendo.2026.1822475.

[2] Halmos G, Szabo Z, Juhasz E, et al. Signaling mechanism of growth hormone-releasing hormone receptor[J]. Vitamins and Hormones, 2023,123:1-26.

DOI:10.1016/bs.vh.2023.06.004.

[3] Montero-Hidalgo A J, Del Rio-Moreno M, Pérez-Gómez J M, et al. Update on regulation of GHRH and its actions on GH secretion in health and disease[J]. Reviews in Endocrine and Metabolic Disorders, 2025,26(3):305-320.

DOI:10.1007/s11154-025-09943-y.

[4] González-López N M, Guerra-Acero-Turizo L M, Blanco-Medina I, et al. In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides[J]. Biomedical Chromatography, 2023,37(12):e5741.

DOI:10.1002/bmc.5741.

[5] Otin J, Tran N T, Benoit A, et al. Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis[J]. Electrophoresis, 2023,44(9-10):807-817.

DOI:10.1002/elps.202200278.

[6] Johannsen C, Nguyen A K T, Shabani S, et al. Development of smart samplers and their comparison to dried serum spots for the analysis of growth hormone releasing hormone analogs using LC-HRMS/MS[J]. Advances in Sample Preparation, 2025,15:100190.

DOI:10.1016/j.sampre.2025.100190.

[7] NCBI PubChem. Sermorelin. PubChem CID 16132413.

ALL PRODUCTS, ARTICLES, TECHNICAL MATERIALS, PRODUCT DESCRIPTIONS, AND OTHER INFORMATION PROVIDED ON THIS WEBSITE ARE INTENDED SOLELY FOR LEGITIMATE LABORATORY RESEARCH, INFORMATIONAL, AND EDUCATIONAL PURPOSES.

Products offered by Cocer Peptides are intended exclusively for in vitro and laboratory research and are NOT intended for human or veterinary use, human consumption, clinical use, diagnostic use, therapeutic use, compounding, self-administration, injection, or any other form of administration to humans or animals. These products are not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition, nor are they intended to affect the structure or function of the human or animal body. Unless expressly stated otherwise, products offered on this website have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. Any references to published studies, biochemical pathways, molecular mechanisms, or experimental findings are provided solely for scientific discussion and research purposes and do not constitute medical advice, therapeutic claims, dosing guidance, or instructions for use. Purchasers are solely responsible for ensuring that all products are acquired, handled, stored, used, and disposed of in accordance with applicable laws, regulations, institutional requirements, and laboratory safety standards.